Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT04899232 Terminated - Covid19 Clinical Trials

Antithrombin III in Infectious Disease Caused by COVID-19

Start date: July 6, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.

NCT ID: NCT04898023 Terminated - Clinical trials for Respiratory Viral Infection

Zinc and Green Tea Extract for Community Respiratory Viral Infections

Start date: September 21, 2022
Phase: Phase 2
Study type: Interventional

Zinc and green tea supplementation have both been independently studied for supporting immune health during cold and flu-like illness in non-hospitalized patients with clinical trials demonstrating promising but inconsistent results. Combination therapy may offer an improved effect as the antioxidant compounds found in green tea have been shown to increase cellular zinc concentrations thereby inhibiting viral replication. This study seeks to evaluate the effect of combination supplementation using established doses of zinc and green tea extract on symptom duration and severity from cold and flu-like illness, including COVID-19, in adult community patients enrolled in a randomized placebo-controlled trial.

NCT ID: NCT04894266 Terminated - COVID-19 Infection Clinical Trials

An Open-Label Study of Apabetalone in Covid Infection

Start date: January 14, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the safety and effect on clinical course of oral apabetalone in hospitalized subjects with Covid-19 infection

NCT ID: NCT04891133 Terminated - COVID-19 Clinical Trials

EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial

Bari-SolidAct
Start date: June 3, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

EU SolidAct is a randomized, multifactorial, adaptive platform trial for COVID-19 and emerging infectious diseases and pandemics. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to hospital with COVID-19. The platform is designed for running phase 2 and phase 3 trials, and with modular data capture (end point/safety data, biobanking, add-on studies) depending on the capacity of participating sites. The study consists of two parts with different primary end points depending on disease stage: EU SolidAct part A includes hospitalized patients with moderate disease, whereas EU SolidAct part B includes hospitalized patients with severe and critical disease.

NCT ID: NCT04877002 Terminated - Covid19 Clinical Trials

Performance Study of SONA Saliva C-19 Rapid Test

Start date: April 29, 2021
Phase: N/A
Study type: Interventional

The Sona Saliva C-19 Rapid Test is a bioassay intended for rapid point-of-care detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to a RT-PCR reference method

NCT ID: NCT04876430 Terminated - Clinical trials for Bloodstream Infection

Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems

ABOVE
Start date: May 4, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

Enterobacterales resistant to carbapenem are cause of severe concern in hospital-acquired infections since therapeutic options are limited. Recently approved drugs, such as bela-lactam/beta-lactamase inhibitor, have been the drug of choice. However, its use is limited in low- and middle-income countries. Thus, therapy of these infections mostly relies on polymyxins and other old drugs. The role of adjuvant carbapenem therapy in combination with polymyxins, aminoglycosides and other drugs is under investigation. From a pharmacokinetic/pharmacodynamic (PK/PD), there is an elevated probability that high-dose, extended infusion administered meropenem reach the PK/PD target of 40% above the minimal inhibitory concentration (MIC) of the pathogen when the MIC is 32mg/L or lower (non-susceptible isolates have MICs of 4mg/L or higher). However, the MIC is not routinely determined in clinical laboratories. In addition, high-level (above 32mg/L) resistance to carbapenems have been reported in many studies. This open-label, randomized clinical trial aim to assess if the addition of meropenem to the best available therapy can increase the number of days alive and free of hospitalization in patients with bloodstream infections by Enterobacterales with MIC of meropenem above 32mg/L.

NCT ID: NCT04847921 Terminated - Clinical trials for Substance Use Disorders

Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition

SUDDEN-OUT
Start date: April 30, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The Investigators aim to study the outcomes of serious infections due to vancomycin susceptible infections in gram-positive organisms susceptible to vancomycin in people who use drugs (PWUD). The Investigators hypothesize, that a simplified 2-dose dalbavancin regimen, will improve compliance with antimicrobial therapy and that it may facilitate engagement in the treatment of the underlying substance use disorder, and particularly injection drug use - often the true etiology behind these severe infections.

NCT ID: NCT04831840 Terminated - Clinical trials for Recurrent Urinary Tract Infection

Recurrent Urinary Tract Infections and the Microbiome

Start date: May 26, 2021
Phase:
Study type: Observational

The primary objective is to determine if polymerase chain reaction (PCR) (UTIP™) is more sensitive in identifying urinary tract infections (UTI's) than standard urine cultures.

NCT ID: NCT04815018 Terminated - Clinical trials for SARS-CoV-2 Infection

Shifts in the Respiratory Microbiome and Clinical Outcomes of SARS-CoV-2

COVID-19
Start date: October 7, 2020
Phase:
Study type: Observational

This is a longitudinal, prospective observational study focusing on health-related outcomes relative to potential changes in the respiratory microbiome seen with weekly SARS-CoV-2 testing in nursing home residents.

NCT ID: NCT04802837 Terminated - Clinical trials for Clostridioides Difficile Infection

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

Ri-CoDIFy 3
Start date: May 19, 2021
Phase: Phase 3
Study type: Interventional

Study to evaluate the safety of ridinilazole in adolescent subjects and how ridinilazole is metabolized.